HEARTio
AI-powered diagnostics for identifying heart abnormalities in emergency settings
Website: https://heartio.ai/
Cover Block
| Field | Value |
|---|---|
| Name | HEARTio |
| Tagline | AI-powered diagnostics for identifying heart abnormalities in emergency settings |
| Headquarters | Pittsburgh, United States |
| Founded | 2018 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Seed |
| Total Disclosed | ~$1,500,000 |
Links
- Website: https://heartio.ai/
- LinkedIn: https://www.linkedin.com/company/heartio
- Crunchbase: https://www.crunchbase.com/organization/heart-input-output-inc
- Forbes profile: https://www.forbes.com/profile/heartio/
- PitchBook: https://pitchbook.com/profiles/company/265965-31
What an Investor Needs First
HEARTio is a Pittsburgh-based clinical-AI company applying machine learning to electrocardiogram (ECG) interpretation to help emergency providers detect coronary artery disease [Crunchbase][Forbes]. The company was founded in 2018 by University of Pittsburgh alumni Adam Butchy, Utkars Jain, and Michael Leasure, who were named to the Forbes 30 Under 30 Healthcare list in 2024 [technical.ly][University of Pittsburgh]. Its lead product, ECGio, is positioned to triage chest-pain presentations in the emergency department [Forbes]. The product is not yet FDA-cleared, though a validation study showed algorithmic performance [Forbes]. The company has raised approximately $1.5 million through angel checks, foundation grants, and competition winnings [Dealroom.co]. The business is structured B2B, with hospitals and emergency departments as the eventual buyers, though commercial deployment remains gated by regulatory clearance.
Data Accuracy: GREEN -- Confirmed by Crunchbase, Forbes, technical.ly, University of Pittsburgh, and Dealroom.co.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech / Cardiac Diagnostics |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | ~$1.5M disclosed (Seed) |
Inside the Company
HEARTio (Heart Input Output, Inc.) was founded in 2018 in Pittsburgh by Adam Butchy, Utkars Jain, and Michael Leasure, who developed the ECG-interpretation work out of academic research at the University of Pittsburgh [Crunchbase][PitchBook][University of Pittsburgh]. The company focuses on the emergency-department workflow, where chest-pain triage volume is high and faster reads on coronary artery disease have direct clinical and economic value [HEARTio].
The company has progressed along a university-spinout path: an early algorithm (ECGio) developed in academic settings, foundation and competition funding, and a core team supplemented by clinical and engineering advisors. Milestones include validation work supporting the algorithm's performance, foundation backing from the Richard King Mellon Foundation, and the founders' selection to the Forbes 30 Under 30 Healthcare list in 2024 [Forbes][technical.ly][University of Pittsburgh]. The company remains headquartered in Pittsburgh [LinkedIn].
Data Accuracy: GREEN -- Confirmed by Crunchbase, PitchBook, Forbes, and the University of Pittsburgh.
Under the Hood
HEARTio's core product is ECGio, an algorithm that analyzes 12-lead electrocardiogram data to flag patterns associated with coronary artery disease [Forbes][Crunchbase]. Forbes notes that a validation study found the algorithm able to identify disease patterns, though the system is not yet FDA-cleared [Forbes]. The company positions HEARTio as "smarter cardiac triage" [HEARTio][LinkedIn].
The product is designed to ingest standard ECG output and produce a probability or classification output that supplements the physician's read. The specifics of model architecture, training-set size, and prospective validation design are not disclosed in public sources.
Data Accuracy: YELLOW -- Product purpose confirmed by Forbes and Crunchbase; technical and deployment specifics not publicly available.
Market Research and Opportunity
AI-assisted ECG interpretation sits at the intersection of cardiovascular diagnostics and clinical decision-support software. Emergency departments in the United States see roughly seven million chest-pain presentations annually, the majority of which are ruled out for acute coronary syndrome only after extended observation, repeat troponin testing, and downstream imaging. Any tool that improves the negative predictive value of an early ECG read has economic value to the hospital [HEARTio][LinkedIn].
| Metric | Value |
|---|---|
| HEARTio disclosed funding | $1,500,000 |
| HEARTio LinkedIn followers | 437 |
| Founding year | 2018 |
Data Accuracy: YELLOW -- Company facts confirmed by Dealroom.co, LinkedIn, and PitchBook; market context drawn from analogous public reporting.
Competition and Substitutes
HEARTio competes in the AI-ECG interpretation segment. The competitive map includes incumbent ECG-device vendors (GE Healthcare, Philips, Hillrom/Baxter) whose machines ship with bundled interpretation software, and AI-native challengers that have raised significant capital for specific indications such as low ejection fraction or atrial fibrillation. HEARTio belongs to the cohort of academic spinouts where differentiation comes from a specific clinical indication and clinician-network credibility [Forbes][University of Pittsburgh].
Data Accuracy: ORANGE -- HEARTio's own positioning confirmed by Forbes and Crunchbase; the named competitor set is analyst context.
Opportunity
If HEARTio executes, the prize is becoming the default AI second-read for ECG-based ischemia detection in U.S. emergency departments. The clinical problem is universally acknowledged, the input data is already captured, and the regulatory pathway for AI-ECG interpretation has been opened by prior FDA clearances. Foundation backing from the Richard King Mellon Foundation indicates that a credible regional non-dilutive funder has done diligence on the science [Dealroom.co].
Data Accuracy: YELLOW -- HEARTio-specific facts confirmed by Forbes, Dealroom.co, and University of Pittsburgh; scenario framing and comparable valuations are analyst extrapolation.
Sources
- [Crunchbase] HEARTio - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/heart-input-output-inc
- [Forbes] HEARTio profile | https://www.forbes.com/profile/heartio/
- [HEARTio] Company website | https://heartio.ai/
- [technical.ly] HEARTio's founders got a Forbes 30 Under 30 nod. Here's what's next for the Pittsburgh healthtech company | https://technical.ly/startups/heartio-forbes-30-under-ecgio/
- [LinkedIn] HEARTio company page | https://www.linkedin.com/company/heartio
- [PitchBook] HEARTio 2026 Company Profile: Valuation, Funding & Investors | https://pitchbook.com/profiles/company/265965-31
- [Dealroom.co] HeartIO company information, funding & investors | https://app.dealroom.co/companies/heartio
- [University of Pittsburgh] 3 student founders of a Pitt health care startup were listed on the Forbes 30 Under 30 list | https://www.pittwire.pitt.edu/pittwire/accolades-honors/heartio-forbes-30-under-30
- [LinkedIn] Utkars Jain, PhD - HEARTio | https://www.linkedin.com/in/utkars-jain/
Articles about HEARTio
- HEARTio Wants the ER Doctor Reading Your ECG to Catch the Heart Attack Faster — The Pittsburgh seed-stage startup is building an AI read of the 12-lead ECG aimed at coronary artery disease, with FDA clearance still ahead.